Seattle Genetics, Inc (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited are the main newsmakers today after they announce positive results in regards to the phase III study, ECHLEON 1 study. It was set up in a bid to evaluate Adcetris (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in the different persons diagnosed with untreated advanced classical Hodgkin lymphoma (HL).
The most exciting part about the whole news was the fact that ECHLEON 1 was able to meet its primary endpoint. Some top researchers in this particular study saw the great need to randomize patients in this study. Of course they were put in line to receive ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine).
A novel combination consisting of Adcetris+AVD (Adriamycin, vinblastine, dacarbazine) showcased remarkable abilities in the removal of bleomycin from the regimen. Later, results were obtained. They clearly indicated that a combination treatment with Adcetris would bring forth the most desirable results. There was an improvement in the control arm versus the modified progression-free survival (PFS).
It is true that the study resulted in positive results, which in a normal case scenario should be something good for the company. However, it was surprising after the company audits were done. Its share price had gone down by almost t 8% according to Yahoo.
A lot of the concerned parties have posed questions wondering how that could be possible. Some top officials have moved forward in a bid to offer an explanation. They have outlined that it might have been as a result of the change in the investor confidence. However, the future might be brighter according to some top analysts.
Adcetris as a matter of fact happens to be the only marketed product at Seattle Genetics and there are a lot of debates among experts regarding it. They are predicting that it will soon help the company rise to the top to become one of the industry leaders.
